|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial显示文摘 | Axel Grothey Eric Van Cutsem Alberto Sobrero Salvatore Siena Alfredo Falcone Marc Ychou Yves Humblet Olivier Bouché Laurent Mineur Carlo Barone Antoine Adenis Josep Tabernero Takayuki Yoshino Heinz-Josef Lenz Richard M Goldberg Daniel J Sargent Frank Ciho | 2012 | The Lancet2012，，： | 10 |
| 2 | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer显示文摘 | Philippe Rougier Hanno Riess Robert Manges Petr Karasek Yves Humblet Carlo Barone Armando Santoro Sylvie Assadourian Laurence Hatteville Philip A. Philip | 2013 | European Journal of Cancer2013，，12： | 4 |
| 3 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer显示文摘 | Cunningham D Humblet Y Siena S | | New England Journal of Medicine0，，： | 3 |
| 4 | A distributed algorithm for minimum weight spanning trees显示文摘 | GALLAGER R HUMBLET P A SPIRA P M | 1983 | ACM Transactions on Programming Languages and Systems1983，5，1： | 1 |
| 5 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer 显示文摘 | CUNNINGHAM D HUMBLET Y SIENA S | 2004 | N Engl J Med2004，351，4： | 1 |
| 6 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan - refractory metastatic colorectal cancer显示文摘 | Cunningham D Humblet Y Siena S | 2004 | N Engl J Med2004，351，4： | 1 |
| 7 | Ce- tuximab monotherapy and cetuximab plus irinote-can in irinotecan refractory metastatic colorectal cancer显示文摘 | CUNNINGHAM D HUMBLET Y SIENA S | 2004 | N Engl J Med2004，351，4： | 1 |
| 8 | Real-time intraoperative assessment of the extrahepatic bile ducts in rats and pigs using invisible near-infrared fluorescent light显示文摘 | TANAKA E CHOI H S HUMBLET V | 2008 | Surgery2008，144，1： | 1 |
| 9 | Cetuximab mono therapy and cetuximah plus irinotecan in irinotecan-refractory metastatic colorecta显示文摘 | Cunningham D Humblet Y Siena S | 2004 | Cancer2004，351，4： | 1 |
| 10 | Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer ( mCRC ) with no or slight skin reactions on cetuximab standard dose treatment ( EVEREST ) : pharmacokinetic (PK) , pharmacodyaamic (PD) and efficacy data显示文摘 | TEJPAR S PEETERS M HUMBLET Y | 2007 | J Clin Oncol2007，25，18： | 1 |
| 11 | Phase I / Ⅱ study of cetuximab dose-escalation inpatients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab stan- dard dose treatment: pharmacokinetic (PK), phar- macodynamic (PD) and efficacy data显示文摘 | TEJPAR S PEETERS M HUMBLET Y | 2007 | J Clin On- col2007，25，18： | 1 |
| 12 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer显示文摘 | Cunningham D Humblet Y Siena S | 2004 | N Engl J Med2004，351，： | 1 |
| 13 | On the bit error rate of lightwave systems with optical amplifiers显示文摘 | HUMBLET P A AZIZOGLU M | 1991 | J of Lightwave Technology1991，9，11： | 1 |
| 14 | Relationship of efficacy with KRAS sta- tus(wild type versus mutant) in patient with irinotecan-re-factory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating does of cetuximab (q1w):The EVEREST experience (preliminary date)显示文摘 | Tejpar S Peeter M Humblet Y | 2008 | J Clin Oncol2008，，： | 1 |
| 15 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer显示文摘 | Cunningham D Humblet Y Siena S | 2004 | N Engl J Med2004，351，4： | 1 |
| 16 | Models of blocking probability in all-optical networks with and without wavelength changers显示文摘 | Barry RA Humblet PA | 1996 | IEEE J Select Areas Commun1996，14，： | 1 |
| 17 | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer显示文摘 | CUNNINGHAM D HUMBLET Y SIENA S | 2004 | N Engl J Med2004，351，4： | 1 |
| 18 | Phase Ⅰ/Ⅱ study of cetuximab dose-escalation in patients with metastatic colorectal cancer(mCRC) with no or slight skin reactions on cetuximab standard dose treatment(EVEREST):Pharmacokinetic(PK),Pharmacodynamic(PD) and efficacy data显示文摘 | Tejpar S Peeters M Humblet Y | 2007 | Proc Am Soc Clin Oncol2007，25，： | 1 |
| 19 | Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuxi mab(qlw) :The EVEREST experince (preliminary date) 显示文摘 | Tejpar S Peetersm Humblet Y | 2008 | J Clin Oncol2008，26，1： | 1 |
| 20 | Wiskott - Aldrich Syndrome Protein is required for regulatory T cell homeostasis 显示文摘 | Humblet - Baron S Sather B Anover S | 2007 | J Clin Invest2007，117，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员